ReviewFrontiers in medicine2026
Pyroptosis-immunity-microbiome axis in acute upper gastrointestinal bleeding: mechanisms, risk prediction, and individualized strategies.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute upper gastrointestinal bleeding (UGIB) is a critical emergency commonly encountered in gastroenterology. Its pathogenesis is complex and involves diverse etiologies. Emerging evidence indicates that pyroptosis, dysregulated immune-inflammatory responses, and gut microbiome imbalance are pivotal mechanisms driving gastric mucosal injury and hemorrhage. This review systematically synthesizes the risk factors, pathophysiological mechanisms, risk prediction models, and therapeutic strategies for UGIB, with particular emphasis on the intricate interplay among pyroptosis, immunity, and the microbiome and on their value as potential therapeutic targets. We first summarize the common etiologies and risk factors of UGIB, including pharmacological agents, infections, advanced age, comorbidities, and genetic predispositions. We then delineate the pathogenic role of pyroptosis in gastric mucosal injury, with particular focus on activation of the GKN2-NLRP3 axis. Next, we discuss the utility of systemic inflammatory markers such as the neutrophil-to-lymphocyte ratio (NLR) and C-reactive protein (CRP) in UGIB risk stratification, together with the mechanisms by which gut microbiome dysbiosis compromises mucosal barrier integrity and amplifies inflammatory responses through microbial metabolites and pathogen translocation. The core section provides an in-depth analysis of the reciprocal, self-amplifying network linking pyroptosis, immune activation, and microbiome perturbation, thereby elucidating the basis for the frequent co-occurrence of systemic inflammation and microbial dysbiosis in UGIB. Finally, we critically evaluate established risk-scoring systems (Glasgow-Blatchford Score, Rockall score, and AIMS65) and emerging biomarkers. Overall, this review assesses emerging therapeutic strategies, including pyroptosis inhibitors and microbiome-modulating interventions, and provides a theoretical framework for personalized management of UGIB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.